Skip to content

Reuters exclusively reports South Korea offers to produce mRNA vaccines


Reuters reported exclusively that South Korea is in talks with mRNA vaccine makers, including Pfizer and Moderna, to produce COVID-19 shots in the country and is ready to offer the capacity to make up to 1 billion doses immediately. The plan, if agreed, would help ease tight global supply of COVID-19 vaccines, particularly in Asia, and put South Korea a step closer to its ambition to become a major vaccine manufacturing center. According to a Reuters source, local vaccine makers, which have the capacity to produce mRNA vaccines immediately, include Hanmi Pharmaceuticals Co Ltd and Quratis Co Ltd.

Market Impact

Shares in Hanmi rose nearly 7% after the Reuters report, and its top shareholder Hanmi Science jumped 10.3%.

Article Tags

Topics of Interest: Health

Type: Reuters Best

Sectors: Pharmaceuticals & Healthcare

Regions: Asia

Countries: South Korea

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Important Regional Story


No comment yet, add your voice below!

Add a Comment

Your email address will not be published. Required fields are marked *